The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises Graphon Labs on $35 Million Series A
On November 10, 2026, Graphon Labs, an applied artificial intelligence (AI) lab building Persistent Intelligence to power the next generation of AI agents and accelerate progress toward artificial general intelligence, announced a $35 million Series A led by RRE Ventures, with participation from HP, Energy Impact Partners, Hitachi Ventures, and Gaia VC. Wilson Sonsini Goodrich & Rosati advised Graphon Labs on the transaction.
Client Highlights
Firm Represents Veteran Ventures Capital as Lead Investor in $6.95 Million Aformic Financing
On November 4, 2026, Veteran Ventures Capital (VVC) announced that it led a $6.95 million investment in Aformic, a robotics company that designs and deploys autonomous mobile robots and fleet-management software. Wilson Sonsini Goodrich & Rosati advised VVC on the transaction.
Client Highlights
Wilson Sonsini Advises Ancep on $8.5 Million Funding Round
On November 10, 2026, Ancep, a London-based start-up building artificial intelligence (AI) agents for commercial insurance brokers, emerged from stealth and announced it raised $8.5 million in a funding round led by Creandum. The round also included participation from Kleiner Perkins and Vicus Ventures, alongside angel investors including Christa Davies, former chief financial officer of Aon, and operators from OpenAI, Anthropic, and Google DeepMind. Ancep will use the new funds to support growth and hiring. Wilson Sonsini Goodrich & Rosati advised Ancep on the transaction.
Client Highlights
Wilson Sonsini Advises HZO on Acquisition by Forge Nano
On November 5, 2026, Forge Nano Holdings, Inc. (Forge Nano), a semiconductor equipment and advanced materials company whose Atomic Layer Deposition (ALD) technology serves AI-era chip manufacturing and defense battery applications, announced that it has completed the acquisition of HZO, Inc., a leading provider of protective nanocoatings for electronics. The combination pairs Forge Nano’s ALD platform with HZO’s high-volume Parylene and thin-film protective coating business and its blue-chip customer base in the consumer electronics, energy, IoT, medical, and automotive industries. Wilson Sonsini Goodrich & Rosati advised HZO on the transaction.
Client Highlights
Wilson Sonsini Advises KymaThera on IP Matters Related to $80 Million Series B
On October 6, 2026, KymaThera, a biotechnology company developing next-generation precision medicines for genetically defined diseases, announced the closing of an $80 million Series B financing led by Alta Partners, with participation from Venrock, Foresite Capital, J. Wood Capital, and others. Wilson Sonsini Goodrich & Rosati advised KymaThera on intellectual property matters related to the financing.
Client Highlights
Wilson Sonsini Advises Skydio on $1.2 Billion Axon Investment
On November 5, 2026, Axon, a global leader in public safety technology, announced an additional $1.2 billion investment in Skydio, the largest U.S.-based drone manufacturer and a world leader in flying robots. The agreement, which will add approximately 20 percent to Axon's fully diluted ownership in Skydio at a $5.2 billion pre-money valuation, builds on a partnership that is already bringing Skydio drones to public safety agencies across the U.S., marking a major expansion of Axon's Drone as First Responder (DFR) program. Axon will also become Skydio's exclusive distributor for public safety in the U.S. and Canada. Wilson Sonsini Goodrich & Rosati advised Skydio on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.